Head and Neck Cancer (HNC) is the sixth most common cancer type accounting for approximately 900,000 cases and over 400,000 deaths annually (Globocan 2021). Heterogeneous malignancies involving the oral nasal cavities, paranasal sinuses, pharynx, larynx, and salivary glands are associated with HNC. The 5-year overall survival rate for Head and Neck Cancers is 64% with median overall survival length ranging from 1.4 to 8.7 years, with glottic larynx cancer having the longest and hypopharynx cancer the shortest. The risk factors most frequently associated with head and neck cancer include smoking, alcohol consumption, diet, human papillomavirus (HPV) and Epstein-Barr virus (EBV) infections. North African and South-Est Asian populations are mostly affected by these types of cancers. Recent estimates predict a major increase (45%-77%) in the number of people which will affected by these types of tumors in the next 20 years.
Through increased understanding on the key factors leading to head and neck cancers, several studies have emphasized on the role of early diagnostic, predictive and prognostic biomarkers for improving survival rates in HNC patients. In lieu of this, genomic, proteomics, metabolic and immunological signatures such as genomic alterations, epigenetic, proteomics, transcriptomics signatures, tumor mutational burden, cytokines, chemokines, soluble mediators, metabolic scores, soluble immune checkpoint and Natural killer cell markers can play a significant role in early detection and monitoring of diseases dynamics. Furthermore, combination of these biomarkers with currently available diagnostic/screening tools could serve helpful in assessing risk and predicting response/progression.
The research topic aims to provide an opportunity to authors to publish original research and review articles in the field of genomics, epigenetics, proteomics, transcriptomics, soluble mediators and immunological biomolecules as diagnostic, predictive and prognostic biomarkers in head and neck cancers.
Early detection, prognosis and prediction of head and neck cancers can play an important role in improving survival rates and treatment dynamics of head and neck cancers.
Recent advances in technologies have helped to understand molecular, metabolic, genetic and proteomic landscape of HNC. In addition to this, the utility of soluble mediators, cytokines, chemokines, soluble immune checkpoint and Natural killer cell markers are considered as non-invasive biomarkers that can be particularly helpful as an alternate to tissue biopsies.
Furthermore, the utility of soluble biomarkers for longitudinal monitoring, treatment dynamics and prediction of response is unprecedented.
The research topic aims to publish research on biomarkers for early detection, prognosis and prediction of treatment dynamics in head and neck cancers.
The research topic aims to provide an opportunity to authors to publish original research and review articles in the field of genomics, epigenetics, proteomics, transcriptomics, soluble mediators and immunological biomolecules as diagnostic, predictive and prognostic biomarkers in head and neck cancers.
Head and Neck Cancer (HNC) is the sixth most common cancer type accounting for approximately 900,000 cases and over 400,000 deaths annually (Globocan 2021). Heterogeneous malignancies involving the oral nasal cavities, paranasal sinuses, pharynx, larynx, and salivary glands are associated with HNC. The 5-year overall survival rate for Head and Neck Cancers is 64% with median overall survival length ranging from 1.4 to 8.7 years, with glottic larynx cancer having the longest and hypopharynx cancer the shortest. The risk factors most frequently associated with head and neck cancer include smoking, alcohol consumption, diet, human papillomavirus (HPV) and Epstein-Barr virus (EBV) infections. North African and South-Est Asian populations are mostly affected by these types of cancers. Recent estimates predict a major increase (45%-77%) in the number of people which will affected by these types of tumors in the next 20 years.
Through increased understanding on the key factors leading to head and neck cancers, several studies have emphasized on the role of early diagnostic, predictive and prognostic biomarkers for improving survival rates in HNC patients. In lieu of this, genomic, proteomics, metabolic and immunological signatures such as genomic alterations, epigenetic, proteomics, transcriptomics signatures, tumor mutational burden, cytokines, chemokines, soluble mediators, metabolic scores, soluble immune checkpoint and Natural killer cell markers can play a significant role in early detection and monitoring of diseases dynamics. Furthermore, combination of these biomarkers with currently available diagnostic/screening tools could serve helpful in assessing risk and predicting response/progression.
The research topic aims to provide an opportunity to authors to publish original research and review articles in the field of genomics, epigenetics, proteomics, transcriptomics, soluble mediators and immunological biomolecules as diagnostic, predictive and prognostic biomarkers in head and neck cancers.
Early detection, prognosis and prediction of head and neck cancers can play an important role in improving survival rates and treatment dynamics of head and neck cancers.
Recent advances in technologies have helped to understand molecular, metabolic, genetic and proteomic landscape of HNC. In addition to this, the utility of soluble mediators, cytokines, chemokines, soluble immune checkpoint and Natural killer cell markers are considered as non-invasive biomarkers that can be particularly helpful as an alternate to tissue biopsies.
Furthermore, the utility of soluble biomarkers for longitudinal monitoring, treatment dynamics and prediction of response is unprecedented.
The research topic aims to publish research on biomarkers for early detection, prognosis and prediction of treatment dynamics in head and neck cancers.
The research topic aims to provide an opportunity to authors to publish original research and review articles in the field of genomics, epigenetics, proteomics, transcriptomics, soluble mediators and immunological biomolecules as diagnostic, predictive and prognostic biomarkers in head and neck cancers.
